Cancer · 1975 · 33 citations · 11 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Toxicity ManagementCombination ChemotherapyCytotoxic ChemotherapySystemic Therapy For Neck CancerToxicity ManagementCombination Drug TherapyDrug Combination Therapy
Several Phase II chemotherapy protocols were evaluated in patients with advanced malignancies; 158 were evaluable head and neck cases. The protocols were as follows: five-drug combination (COMFP), four-drug (COMF), (CCNU, Adriamycin, DTIC, and cytosine arabinoside. Insufficient numbers and data were received to adequately evaluate Yoshi 864, 5 Azacytidine, porfiromycin, BCNU, and Azaserine. Significant responses to therapy were noted in the four and five-drug combinations in which 30-44% of the patients had 50% or greater regression, with an average duration of 2.2 months. Adriamycin and CCNU demonstrated lesser antitumor effects, while DTIC and cytosine arabinoside did not demonstrate significant antitumor activity in the head and neck areas. Usual toxicity consisted largely of nausea and vomiting, leukopenia, and thrombocytopenia. Alopecia was not pronouced in Adriamycin-treated patients. It appears that combination chemotherapy had a higher response rate compared to single agents used in the different cooperative protocols.
11
Phase II evaluation of adriamycin in human neoplasia
Robert M. OʼBryan, James K. Luce, Robert W. Talley et al. · Cancer · 1973 · 417 citations · Full text
Medicine, Oncology, Pharmacology +14
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
Charlotte Tan, Erlinda Etcubanas, Norma Wollner et al. · Cancer · 1973 · 238 citations · Full text
Medicine, Oncology, Pharmacology +15
Chemotherapy of cancer of the head and neck
Joseph R. Bertino, Michael B. Mosher, Ronald C. DeConti · Cancer · 1973 · 125 citations
Medicine, Oncology, Pharmacology +7